Traditional vaccines are less reliableIn populations which require them most, such as neonates and elderly adults. Vaccine adjuvant is one way to enhance antigen immunogenicity in diminished immunity populations. Vaccine adjuvants would ideally improve the population-wide seroconversion rate and contribute to greater immune responses, and enable less vaccine-dose administration. In comparison to commercial vaccine, the study has shown that cationical liposomal formulation of the CCS/C-HA (Commercial Influenza Split Virus Vaccine) strengthened the cellular and humoral immunity to the virus, increased seroconversion and improved survival following the live virus challenge (F-HA). They have now assessed the vaccine effectiveness in various strains and sexes of the mice by checking for the responsiveness of mice with defective Toll-like receptors or the MyD 88 T LR/IL-1 adaptors following immunisation with CCS/C-HA vs. F-HA and have established the role of innate immunity in the mechanism of action of the CCS/C adjuvant.
In the absence of MyD88, the immune system F-HA has not caused any major immune reaction, while TLR2 and TLR4 deficient mice have responded to F-HA immunisation. In comparison, vaccination with CCS/C-HA has overcome myD88 response requirement and increased immune reactions and seroconversion rates in all mice strains studied, including TLR2 and TLR4 deficiencies.
Reference: https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1750247
